J&J's Tremfya Shines in Psoriatic Arthritis Study

Johnson & Johnson recently announced positive top-line findings from its Phase 4 STAR study for Tremfya (guselkumab) in adults with active psoriatic arthritis and axial involvement. The study met its primary and secondary goals, showing Tremfya's efficacy in improving axial symptoms and reducing joint inflammation as confirmed by MRI. This marks a significant step as it's the first randomized, placebo-controlled trial to use objective MRI assessments for an IL-23 inhibitor in this patient group.

The study's success reinforces Johnson & Johnson's strategy to grow its key immunology products. In the second quarter of 2026, the company reported robust operational sales growth of 5.6%, reaching $25.3 billion, with its Innovative Medicine segment performing strongly, propelled by Tremfya alongside other blockbusters. Building on this momentum, J&J increased its full-year 2026 sales forecast to a midpoint of $101.1 billion.

However, the company faces challenges. Declining sales of Stelara, its legacy biologic, due to biosimilar competition, presented a significant drag on growth. J&J's MedTech division also experienced moderated growth, indicating sensitivity to market dynamics. While Tremfya's positive trial data broadens its patient population, its market uptake must accelerate to offset revenue losses from older products and navigate ongoing litigation and restructuring costs.